SENP2 is a protease catalyzing two essential functions in the SUMO pathway: hydrolysis of SUMO propeptides (SUMO1, SUMO2, SUMO3) to generate their mature forms, and deconjugation of mature SUMO proteins from target substrates. SENP2 localizes to the nuclear pore through interaction with nucleoporin Nup153, which regulates its activity over a subset of nuclear SUMO conjugates 1. The enzyme modulates diverse cellular processes including adipogenesis by desumoylating CEBPB to promote its stabilization, and Wnt signaling through CTNNB1 regulation. Recent studies reveal SENP2's emerging roles in disease-relevant contexts. In myocardial ischemia-reperfusion injury, SENP2 removes SUMOylation of NCOA4, protecting cardiomyocytes from ferroptosis-dependent cell death and promoting cardiac function recovery 2. In activated T cells, VEGF-B signaling induces SENP2 expression, which desumoylates PPARγ to enhance phospholipid synthesis and maintain mitochondrial fitness 3. In primary human adipocytes, SENP2 knockdown reduces glucose metabolism and lipid accumulation while increasing lipid oxidation 4. Conversely, in breast cancer, SENP2 promotes tumorigenesis by deconjugating ERK2 SUMOylation, preventing ERK2 degradation and epithelial-to-mesenchymal transition; microRNA-145-5p suppresses this pathway 5. SENP2 also regulates the epithelial mitosis-differentiation checkpoint controlling squamous cancer development 6.